格隆汇8月1日丨科笛-B(02487.HK)公告,集团的CU-40102(外用非那雄胺喷雾剂)已获得中国香港特别行政区政府卫生署上市批准,获批的适应症为治疗雄激素性脱发。这是CU-40102继取得中国国家药品监督管理局上市批准后又一重大进展。非那雄胺作为特异性II型5α-还原酶竞争抑制剂抑制头皮中睾酮转化为双氢睾酮,可治疗雄激素性脱发。与口服非那雄胺不同,CU-40102的外用制剂便于患者将药物...
Source Link格隆汇8月1日丨科笛-B(02487.HK)公告,集团的CU-40102(外用非那雄胺喷雾剂)已获得中国香港特别行政区政府卫生署上市批准,获批的适应症为治疗雄激素性脱发。这是CU-40102继取得中国国家药品监督管理局上市批准后又一重大进展。非那雄胺作为特异性II型5α-还原酶竞争抑制剂抑制头皮中睾酮转化为双氢睾酮,可治疗雄激素性脱发。与口服非那雄胺不同,CU-40102的外用制剂便于患者将药物...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.